Overview

Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts

Status:
Completed
Trial end date:
2010-07-15
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the effectiveness of destructive therapy for anogenital warts in combination with the use of Ingaron in comparison with destructive therapy.
Phase:
Phase 3
Details
Lead Sponsor:
SPP Pharmaclon Ltd.
Treatments:
Interferon-gamma
Interferons